Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

[31] Schleifman E(2019)Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial Ann. Oncol. 30 281-588

[32] Zou W(2018)Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression J. Clin. Invest. 128 805-2426

[33] Li Y(2018)PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression J. Clin. Invest. 128 580-10126

[34] Hellmann MD(2017)First-line nivolumab in stage iv or recurrent non-small-cell lung cancer N. Engl. J. Med. 376 2415-691

[35] Ciuleanu TE(2018)Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) Proc. Natl Acad. Sci. USA 115 10119-538

[36] Pluzanski A(2017)Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples Clin. Lung Cancer 18 682-153

[37] Lee JS(2017)Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy Mod. Pathol. 30 530-708

[38] Otterson GA(2016)Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies Ann. Oncol. 27 147-148

[39] Audigier-Valette C(2018)Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas Appl. Immunohistochem. Mol. Morphol. 26 701-615

[40] Garon EB(2012)Impact of collection and storage of lung tumor tissue on whole genome expression profiling J. Mol. Diagn. 14 140-1331

[31] Schleifman E(2019)Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial Ann. Oncol. 30 281-588

[32] Zou W(2018)Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression J. Clin. Invest. 128 805-2426

[33] Li Y(2018)PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression J. Clin. Invest. 128 580-10126

[34] Hellmann MD(2017)First-line nivolumab in stage iv or recurrent non-small-cell lung cancer N. Engl. J. Med. 376 2415-691

[35] Ciuleanu TE(2018)Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) Proc. Natl Acad. Sci. USA 115 10119-538

[36] Pluzanski A(2017)Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples Clin. Lung Cancer 18 682-153

[37] Lee JS(2017)Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy Mod. Pathol. 30 530-708

[38] Otterson GA(2016)Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies Ann. Oncol. 27 147-148

[39] Audigier-Valette C(2018)Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas Appl. Immunohistochem. Mol. Morphol. 26 701-615

[40] Garon EB(2012)Impact of collection and storage of lung tumor tissue on whole genome expression profiling J. Mol. Diagn. 14 140-1331